Bayer’s Nubeqa Secures Third FDA Approval, Expanding Prostate Cancer Treatment Landscape Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted approval for a third indication of…
Takeda Secures European Commission Approval for ADCETRIS® in Combination with ECADD as a New Frontline Therapy for Adults with Advanced-Stage Hodgkin Lymphoma Takeda has announced a major milestone in the…
ASCO 2025: Subcutaneous Sarclisa with On-Body Injector Shows Promise in Multiple Myeloma Treatment At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Sanofi presented promising data from two…
AbbVie Launches Second Annual Migraine Career Catalyst Award to Empower People with Migraine in Pursuit of Their Professional Dreams Pharmaceutical company AbbVie has announced the return of its AbbVie Migraine…
Roche Announces Positive Phase III IMforte Study Results: Tecentriq Combined with Lurbinectedin Demonstrates Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer Roche today reported promising outcomes from the pivotal…
Eli Lilly Presents Promising Phase 1 Data for Investigational FRα-Targeting ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025 Eli Lilly and Company has announced encouraging new Phase 1 clinical data…
Biotech Industry Sounds Alarm on Trump Tariffs, Citing Threats to Rare Disease and Advanced Therapies Despite billions of dollars being funneled into reshoring pharmaceutical manufacturing to U.S. soil, the biotech…
BioNTech and Bristol Myers Squibb Forge $11.1 Billion Global Partnership to Advance Bispecific Cancer Antibody BNT327 Across Multiple Solid Tumor Types In a move that signals a major step forward…
Genmab Unveils Promising Phase 1/2 Data for Rina-S® in Heavily Pretreated Advanced Endometrial Cancer at ASCO 2025 Genmab A/S, a leading biotechnology company specializing in antibody-based therapies for cancer, has…
BeOne Medicines Showcases Early Clinical Success of Two Innovative Breast Cancer Therapies at ASCO 2025 BeOne Medicines Ltd. a global biotechnology company dedicated to developing targeted therapies for cancer, announced…
Viatris Reports Positive Phase 3 Results for MR-142, Advancing a Potential First-in-Class Treatment for Night Vision Impairment in Keratorefractive Patients Viatris Inc. a global healthcare company committed to bridging access…
Jazz Pharmaceuticals Reports Landmark Phase 3 Results for Zepzelca and Tecentriq Combo as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc has announced highly promising results…